There are obvious parallels between cannabis and psychedelics decriminalization. Are there are also differences?
Exploring the companies and themes that make up this emerging and exciting new sector
Mydecine Innovations Group Provides Inaugural Corporate Update in the Expanding Psychedelic Medicines Sector
Mydecine's corporate update notes its "world's first" clinical trials initiative for PTSD.
GHP Noetic Science-Psychedelic Pharma Inc. Announces Closing of Initial Public Offering
A new psychedelics company began trading August 11th.
MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy
MindMed adds a psychedelics therapy expert to its LSD research program.
4 Palliative Canadians approved for end of life psilocybin therapy through section 56(1) ; First legal medical exemptions for psilocybin in Canada since 1970s
LEGAL use of psilocybin in Canada for the first time in nearly 50 years.
Going To War For Legal Psychedelic Drugs
The need for the medicinal benefits of psychedelic drugs is producing unlikely allies.
Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness
Mydecine's Vancouver-based affiliate, Mindleap Health™ is adding three digital therapy programs.
Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.
Novamind acquires Utah-based Cedar Psychiatry and Cedar Clinical Research for CAD$3.05 million.
Big Pharma: Friend or Foe of Psychedelic Drugs?
Big Pharma has strong incentives to embrace psychedelics. But will its predatory business model turn drug companies against these drugs?
Palliative Canadians endure punishing waits while Health Minister delays approval of Psilocybin mushrooms; TheraPsil expands effort to Ontario
More pressure on Ottawa to move forward on legalization of psilocybin.
Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness
Numinus establishes a partnership with one of Canada's largest addiction treatment organizations.
MindMed Completes Dosing 18-MC Phase 1 Study
MindMed completes its Phase 1 study of its non-hallucinogenic formulation of ibogaine.